MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study
Year: 2018
Type: article
Abstract: BACKGROUND: With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (AD), there is an urgent need for reliable, non-invasive biomarkers to predict amyloid pathology. The aim of this study was to assess whether easily obtainable measures from structural MRI, combined with demographic data, cognitive data and apolipoprotein E (APOE) ε4 genotype, can be used to predict amyloid pathology using machine-learning classification. METHODS: We examined 810 subjects with structural MRI data and amyloid markers from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, including subjects with normal cognition (CN, n = 337, age 66.5 ± 7.2, 50% female, 27% amyloid positive), mild cognitive impairment (MCI, n = 375, age 69.1 ± 7.5, 53% female, 63% amyloid positive) and AD dementia (n = 98, age 67.0 ± 7.7, 48% female, 97% amyloid positive). Structural MRI scans were visually assessed and Freesurfer was used to obtain subcortical volumes, cortical thickness and surface area measures. We first assessed univariate associations between MRI measures and amyloid pathology using mixed models. Next, we developed and tested an automated classifier using demographic, cognitive, MRI and APOE ε4 information to predict amyloid pathology. A support vector machine (SVM) with nested 10-fold cross-validation was applied to identify a set of markers best discriminating between amyloid positive and amyloid negative subjects. RESULTS: In univariate associations, amyloid pathology was associated with lower subcortical volumes and thinner cortex in AD-signature regions in CN and MCI. The multi-variable SVM classifier provided an area under the curve (AUC) of 0.81 ± 0.07 in MCI and an AUC of 0.74 ± 0.08 in CN. In CN, selected features for the classifier included APOE ε4, age, memory scores and several MRI measures such as hippocampus, amygdala and accumbens volumes and cortical thickness in temporal and parahippocampal regions. In MCI, the classifier including demographic and APOE ε4 information did not improve after additionally adding imaging measures. CONCLUSIONS: Amyloid pathology is associated with changes in structural MRI measures in CN and MCI. An automated classifier based on clinical, imaging and APOE ε4 data can identify the presence of amyloid pathology with a moderate level of accuracy. These results could be used in clinical trials to pre-screen subjects for anti-amyloid therapies.
Source: Alzheimer s Research & Therapy
Authors: Mara ten Kate, Alberto Redolfi, Enrico Peira, Isabelle Bos, Stephanie J. Vos, Rik Vandenberghe, Silvy Gabel, Jolien Schaeverbeke, Philip Scheltens, Olivier Blin, Jill C. Richardson, Regis Bordet, Anders Wallin, Carl Eckerstrom, José Luis Molinuevo, Sebastiaan Engelborghs, Christine Van Broeckhoven, Pablo Martinez-Lage, Julius Popp, Magdalini Tsolaki, Frans R. J. Verhey, Alison L. Baird, Cristina Legido-Quigley, Lars Bertram, Valerija Dobricic, Henrik Zetterberg, Simon Lovestone, Johannes Streffer, Silvia Bianchetti, Gerald P. Novak, Jerome Revillard, Mark F. Gordon, Zhiyong Xie, Viktor Wottschel, Giovanni Frisoni, Pieter Jelle Visser, Frederik Barkhof
Institutions: Amsterdam UMC Location Vrije Universiteit Amsterdam, Centro San Giovanni di Dio Fatebenefratelli, Maastricht University, Universitair Ziekenhuis Leuven, KU Leuven, Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, GlaxoSmithKline (United Kingdom), Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, University of Gothenburg, Pasqual Maragall Foundation, Barcelonaβeta Brain Research Center, University of Antwerp, ZNA Middelheim Hospital, Institute Born-Bunge, VIB-UAntwerp Center for Molecular Neurology, Fundacion CITA Alzheimer, Centre Hospitalier Universitaire Vaudois, University Hospital of Geneva, Aristotle University of Thessaloniki, G. Papanikolaou General Hospital, University of Oxford, King's College London, University of Oslo, Imperial College London, University of Lübeck, Sahlgrenska University Hospital, UK Dementia Research Institute, National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, University College London, UCB Pharma (Belgium), Teva Pharmaceuticals (United States), Boehringer Ingelheim (United States), Pfizer (United States), University of Geneva
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Keywords: amyloid pathology, Alzheimer's disease, structural MRI, amyloid biomarkers, mild cognitive impairment, pre-dementia, APOE ε4, subcortical volume, cortical thickness, hippocampus, amygdala, accumbens, support vector classifier, multimodal biomarkers, non-invasive prediction, machine learning classification
Open Access status: gold
Estimated APC paid: $4,290
Funders: European Federation of Pharmaceutical Industries and Associations, National Institute for Health and Care Research, European Commission, National Research Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, ZonMw, Eusko Jaurlaritza, Fonds Wetenschappelijk Onderzoek, Sahlgrenska Universitetssjukhuset, Universiteit Antwerpen, University College London Hospitals NHS Foundation Trust, Stichting Dioraphte, Alzheimer Nederland, Vlaamse regering
Awards: G1073258374, G1553864662, G1901141725, G2473961061, Macrophage migration inhibitory factor and neuroinflammation in early Alzheimer’s Disease, Data-driven models for Progression Of Neurological Disease, Physical and chemical properties of clusters in a molecular beam and deposited in a matrix or on a surface, Flächensparen beim Verkehr, G6382720711, European Medical Information Framework, G880118091
OpenAlex ID: W2894000069
